Klebsiella pneumoniae M1803, isolated from a paediatric patient with chronic urinary infection, presented nine antimicrobial resistance mechanisms harboured on two conjugative megaplasmids, in addition to the chromosomally mediated SHV-1 β-lactamase. These nine antimicrobial resistance mechanisms comprised two extended-spectrum β-lactamases (ESBLs) (PER-2 and CTX-M-2), TEM-1-like, OXA-9-like, AAC(3)-IIa, AAC(6′)-Ib, ANT(3″)-Ia and resistance determinants to tetracycline and chloramphenicol. During fluoroquinolone treatment, a variant derived from M1803 (named M1826) was selected, with an overall increase of MICs, in particular of cefoxitin and carbapenems. No enzymic activity against these latter drugs was found. Mutations in the region analogous to the quinolone resistance-determining region were not found. Strain M1826 was deficient in OmpK35/36 expression, which produced the decrease in the susceptibility to cefoxitin, carbapenems and fluoroquinolones. The bla CTX-M-2 gene was located in an unusual class 1 integron, which includes Orf513, as occurred in the recently described In35. In addition, Tn3 and Tn1331 were detected in both K. pneumoniae isolates. This is the first report of in vivo selection of an OmpK35/36 deficiency in a K. pneumoniae strain that produced a novel combination of two ESBLs (CTX-M-2 and PER-2) during fluoroquinolone treatment in a paediatric patient with chronic urinary infection.
Introduction
Klebsiella pneumoniae is a common nosocomial pathogen causing severe morbidity and mortality in paediatric patients. Most K. pneumoniae isolates have a chromosomally encoded SHV-1 β-lactamase. 1 Since 1983, plasmid-encoded extended-spectrum β-lactamases (ESBLs) derived from the TEM and SHV families have been extensively reported in Enterobacteriaceae, especially in Klebsiella spp. 2, 3 Although ESBLs have been identified in Argentina, their prevalences are different from those observed in other countries. A national surveillance of extended-spectrum cephalosporin resistance in Klebsiella spp. was performed through the WHONETLaboratory Network Argentina. The unique ESBLs detected among the 200 isolates analysed in this surveillance were CTX-M-2-like (>60% of isolates) and PER-2-like, SHV-5-like and SHV-2-like (∼10% of isolates in each case). 4 K. pneumoniae producing two or more ESBLs have been reported scarcely, but when they are, in most cases they include TEM-and/or SHV-derived enzymes. [5] [6] [7] [8] [9] [10] [11] Herein we report the characterization of a multiresistant K. pneumoniae isolate that produces a novel combination of two ESBLs (CTX-M-2 and PER-2) and a derived variant of this strain, which was selected during ciprofloxacin treatment and showed alterations in the expression levels of outer membrane proteins (OMPs).
Materials and methods

Patient and bacterial strains
K. pneumoniae M1803 and M1826 were isolated from a 1-year-old patient who suffered chronic urinary tract infection due to a posterior urethral valve malformation and bilateral vesicourethral reflux. During a period of 5 months, the child was treated for successive urinary infections with amphotericin (Gador, Buenos Aires, Argentina), ceftriaxone (Roche), furazolidone (nitrofurantoin analogue; Schering-Plough), amoxicillin (Roche), imipenem (imipenem/cilastatin; Merck Sharp & Dohme) and ciprofloxacin (Bayer). During one of these infections, K. pneumoniae strain M1803 was isolated. After 10 days of ciprofloxacin therapy, K. pneumoniae strain M1826 was isolated.
Escherichia coli ER1793 [F -fhuA2 ∆(lacZ)r1 glnV44 e14 -(McrA -) trp-31 his-1 rpsL104(Str R ) xyl-7 mtl-2 metB1 ∆(mcrC-mrr)114::IS10; New England Biolabs, Beverly, MA, USA], resistant to nalidixic acid and rifampicin, was employed as the recipient strain in conjugative assays.
Antimicrobial agents and susceptibility testing
The antimicrobial agents used for susceptibility testing were obtained from standard laboratory powders, and their sources were as follows: amikacin, aztreonam and cefepime (Bristol-Myers Squibb); amoxicillin and clavulanic acid (Smith Kline Beechman and Roemmers, Buenos Aires, Argentina); ampicillin (Temis Lostaló, Buenos Aires, Argentina); chloramphenicol (Parke Davis, Buenos Aires, Argentina); cefotaxime (Argentia, Buenos Aires, Argentina); cefoxitin and imipenem (without cilastatin) (Merck Sharp & Dohme); ceftazidime (Glaxo); ceftibuten, gentamicin, sulfamethoxazole and trimethoprim (Schering Plough); cefalothin, piperacillin and tazobactam (Wyeth Pharmaceuticals); tetracycline (Microsules and Bernabó, Buenos Aires, Argentina); meropenem (Astra Zeneca); and ciprofloxacin (Bagó, Buenos Aires, Argentina). The antimicrobial susceptibility of each isolate and its transconjugants was determined by the disc diffusion and agar dilution methods according to NCCLS guidelines. 12-15 When indicated, clavulanic acid (2 mg/L) or tazobactam (4 mg/L) was used in combination with β-lactams. Table 1 . Primers for PCR analysis of antimicrobial resistance mechanisms F, forward; R, reverse. a Numeration corresponding to primers employed in PCR mapping (see Figure 3) . Isoelectric focusing and microbiological method for detection of β-lactamases β-Lactamase preparation and analytical isoelectric focusing (IEF) were performed as described previously. 16 β-Lactamase bands were visualized by the iodometric method described by Labia & Barthélémy. 17 For β-lactamase inhibition procedures the gel was covered with a piece of filter paper impregnated with 1 mM clavulanic acid, aztreonam or cefoxitin as indicated, and incubated for 10 min at room temperature before developing as described above. Crude preparations from bacteria possessing β-lactamases of known isoelectric points (pI) were used as standards: TEM-1 (pI 5.4), PER-2 (pI 5.4), SHV-2 (pI 7.6), P99 (pI 7.8), CTX-M-2 (pI 7.9) and SHV-5 (pI 8.2).
The hydrolytic activity against cefoxitin and carbapenems was determined by the microbiological method. 18 
OMP analysis
OMPs were isolated as sodium lauroyl sarcosynate-insoluble material from cell envelopes after sonication (20 pulses of 30 s in ice at 30 s intervals) and centrifugation of lysed cells at 100 000g for 1 h at 4°C. 19 Electrophoretic analysis of OMPs was performed as previously reported, 19 using 12% SDS-PAGE gels and broad molecular weight markers (unstained; Bio-Rad, Hercules, CA, USA) as standards.
Conjugative assays
Biparental conjugations were performed by mixing the donor and recipient strains on Luria-Bertani agar in a ratio of 5:1, and incubating the mixture for 18 h at 35°C. Transconjugants were selected on MuellerHinton agar supplemented with nalidixic acid (50 mg/L) plus cefotaxime (8 mg/L), or nalidixic acid plus ceftazidime (15 mg/L).
General molecular biology procedures
The relatedness of K. pneumoniae M1803 and M1826 was assessed by pulsed-field gel electrophoresis (PFGE) of the XbaI-digested DNA using conditions already described. 20 Plasmid DNA was extracted from K. pneumoniae and E. coli transconjugant cells as described previously, 21 and were analysed by electrophoresis in 0.7% agarose gels (Tris-acetate buffer), employing plasmids of known size as standards.
PCR assays
Detection of antimicrobial resistance genes was performed by PCR using the forward and reverse primers listed in Table 1 . DNA templates were prepared by lysing one or two colonies of each K. pneumoniae isolate, or each E. coli transconjugant, in 50 µL of boiling water, and 2 µL was used for the PCRs. Amplifications were performed with a Biometra thermal cycler (Whatman Biometra GmbH, Göttingen, Germany) in a final volume of 50 µL containing 20 pmol of each primer (purchased from Gibco-BRL, Gaithersburg, MD, USA), 25 µM of each dNTP, 1.5 mM MgCl 2 and 2.5 U of Taq polymerase (Promega, Madison, WI, USA). Previously described conditions for cycling were used. 16, 22, 23 DNA sequencing DNA sequencing of amplicons obtained with primers specific to bla CTX-M , bla PER and gyrA [including the region analogous to the quinolone resistance-determining region (QRDR)] genes (Table 1) was performed on both strands by the method of Sanger et al., 24 using the BigDye terminators methodology (Applied Biosystems/Perkin Elmer, Foster City, CA, USA). The sequences were analysed in an ABI Prism 377 DNA Sequencer (Applied Biosystems/Perkin Elmer).
Results and discussion
Antibiotic susceptibility and plasmid profiles of K. pneumoniae M1803 and M1826, and E. coli transconjugants K. pneumoniae M1803 and M1826 showed less than three differences according to PFGE profiling, indicating the clonal relationship between both isolates (Figure 1 ). 25 In contrast to M1803, isolate M1826 was resistant to cefoxitin and ceftibuten, showing a 4-32× increase in the MICs of extended-spectrum cephalosporins, carbapenems, aztreonam, piperacillin-tazobactam, chloramphenicol and ciprofloxacin. In addition, clavulanic acid produced almost no reduction in the MICs of extended-spectrum cephalosporins against isolate M1826 (Table 2) .
For strains M1803 and M1826, two different types of E. coli transconjugants were obtained, named type 1 and type 2 ( Table 2) . Type 1 transconjugants (M3089 and M3090, derived from M1803 and M1826 strains, respectively) were selected with nalidixic acid plus cefotaxime, and were resistant to cefotaxime, cefepime and gentamicin. Type 2 transconjugants (M3129 and M3130, derived from M1803 and M1826 strains, respectively) were selected with nalidixic acid plus ceftazidime, and were resistant to ceftazidime, ceftibuten, chloramphenicol, tetracycline and gentamicin, and showed Table 2 . It is noteworthy that the segregation of different non-β-lactam susceptibility profiles into type 1 and 2 transconjugants occurred in the absence of any selective pressure. The most probable explanation for this fact would be the coexistence of two different megaplasmids of the same size (i.e. 140 kb) in each of the two parental K. pneumoniae isolates, each carrying a different complement of β-lactam and non-β-lactam resistance genes.
Characterization of β-lactamases produced by K. pneumoniae M1803 and M1826
By IEF analysis, with the β-lactamase bands being visualized by an iodometric method using ampicillin plus cefaloridine as substrate, three bands were detected in both K. pneumoniae strains, with pIs of 5.4, 7.6 (corresponding to the chromosomal SHV-1 β-lactamase) and 7.9 ( Table 2 ). In contrast, when visualizing the β-lactamase bands with ceftazidime, two bands were detected, with pIs of 5.4 and 7.9. All bands were susceptible to clavulanic acid inhibition. The nature of a broad-spectrum β-lactamase activity with a pI of 5.4 could not be specifically determined in these standard IEF assays because of an overlapping ESBL band at the same pI. Accordingly, in situ β-lactamase inhibition using cefoxitin was performed on the IEF gel, as described previously. 16 The ESBL activity with a pI of 5.4 was inhibited with cefoxitin, whereas the broad-spectrum β-lactamase activity with a pI of 5.4 and the ESBL activity with a pI of 7.9 were not. This property, of cefoxitin inhibition of the ESBL band at pI 5.4, indicated it was most likely to be the PER-2 enzyme. These results are in agreement with those obtained by PCR assays, which yielded amplification products with primers specific to TEM, SHV, CTX-M and PER families of β-lactamases genes. Therefore, the presence of four β-lactamase genes, bla PER-2 -like, bla CTX-M-2 -like, bla SHV-1 -like 
and bla TEM-1 -like, was confirmed. These results were replicated using both types of transconjugant strains to determine which β-lactamase gene is encoded for on which plasmid ( Table 2 ). The identity of bla PER-2 and bla CTX-M-2 genes was unequivocally established by sequencing of the corresponding amplicons (data not shown).
Non-transferable antibiotic resistance caused by an OmpK35 and OmpK36 deficiency in K. pneumoniae M1826
K. pneumoniae isolates that are resistant to cefoxitin have been described previously, with resistance caused by either the production of a plasmid-mediated AmpC-like β-lactamase 26, 27 or the loss of OMPs, such as OmpK35 and OmpK36. 19, 28 Indeed, reduced expression of both porins has been reported in K. pneumoniae strains with high MICs of cefoxitin (>32 mg/L). 28 Moreover, increase in the levels of resistance to extended-spectrum cephalosporins, carbapenems and also fluoroquinolones other than cefoxitin, has been associated to the loss of both OmpK35 and OmpK36. 19, 29, 30 In this study, the genetic determinants of K. pneumoniae M1826 conferring resistance to cefoxitin and carbapenems could not be transferred to E. coli by conjugation. Furthermore, incubation of the IEF gels with aztreonam (an AmpC-like β-lactamase inhibitor), prior to β-lactamase visualization using ampicillin plus cefaloridine, did not result in inhibition of any of the β-lactamase bands produced by K. pneumoniae M1826 (data not shown). This fact suggests the absence of enzymic activity against cefoxitin in this isolate. Indeed, using a microbiological method, no enzymic activity against cefoxitin and carbapenems was detected in K. pneumoniae M1826. In this assay, the parallel control was a crude extract containing the known AmpC MIR-1, and this showed a positive result for cefoxitin hydrolysis. All this information suggests the absence of AmpC-type enzymes in K. pneumoniae M1826, and that cefoxitin resistance was chromosomal.
Accordingly, OMP analysis for K. pneumoniae M1803 and M1826 (cefoxitin MICs of 2 and 64 mg/L, respectively) was performed and showed that the latter was deficient in OmpK35/36 expression ( Figure 2) . Our results are in agreement with the previous reports mentioned above, suggesting that the deficiency in OmpK35/ 36 expression is responsible for the higher overall resistance levels displayed by the M1826 isolate (particularly to cefoxitin and carbapenems) as compared with those of the pretreatment M1803 isolate ( Table 2) .
The partial sequencing of gyrA from K. pneumoniae M1826, including the QRDR, did not reveal mutations at codons 83 and 87, indicating that the increased levels of fluoroquinolone resistance in this mutant are not associated with these target site alterations, and are probably a result of the observed loss of OmpK35/36. Increased expression of efflux mechanisms cannot be completely discounted, however.
Detailed analysis of the transferable resistance genes carried by K. pneumoniae M1803 and M1826
Very recently, the bla CTX-M-2 gene has been reported as being located in unusual class I integrons In35 and InS21, in clinical isolates of Proteus mirabilis and Salmonella enterica ser. Infantis, respectively. 30, 31 This unusual class 1 integron contains a partial duplication of the 3′ conserved segment, and a region that includes bla CTX-M-2 and the Orf513 between both 3′ conserved segments. In addition, In35-related integrons having bla CTX-M-2 in conjunction with different resistance cassettes such as aac (6′) 30 In the present work, by PCR mapping of both K. pneumoniae isolates and the type 1 transconjugants, the bla CTX-M-2 gene was located in an unusual class 1 integron having ant(2″)-Iaant(3″)-Ia gene cassettes within the variable region (Figure 3a) . The co-existence of bla CTX-M-2 and ant(2″)-Ia genes in the same genetic structure (a complex sulI-type integron) and harboured, in turn, in a conjugative megaplasmid, may explain the high prevalence in our bacterial population of both extended-spectrum cephalosporin and gentamicin resistance. The widespread distribution of CTX-M-2-like enzymes among clinical isolates of K. pneumoniae in Argentina (60%) 4 could be explained by the fact that ceftriaxone and cefotaxime are the most used cephalosporins in our country. Another gene conferring resistance to gentamicin, aac(3)-IIa, was found in both type 1 and type 2 transconjugants. The finding of two gentamicin resistance genes [ant(2″)-Ia and aac(3)-IIa] in type 1 transconjugants correlated well with an MIC of gentamicin 8-fold higher than that observed for type 2 transconjugants (Table 2) .
TEM-1 is the most widespread plasmid-mediated β-lactamase around the world, because its structural gene is harboured on the Tn3 transposon. Tn1331 is a transposable element belonging to the Tn3 family that carries, in addition to bla TEM-1 , another β-lactamase gene (bla ) and two genes encoding aminoglycoside-modifying enzymes: aac(6′)-Ib and ant(3″)-Ia (Figure 3b) . 32 By PCR mapping, three amplification products of Tn1331 were produced using templates from both K. pneumoniae isolates in this study (Table 2 ; Figure 3b ). Interestingly, Tn1331 was only detected in the type 2 transconjugants, while in the type 1 transconjugants, the bla TEM-1 -like gene was located in Tn3 by PCR with primers to tnpA and bla TEM (OT-2) genes ( Table 2 ). These data also support the hypothesis of the existence of two different megaplasmids of the same size in each of the two parental K. pneumoniae isolates (one of them harbouring Tn1331 and the other Tn3), which can be separately transferred by conjugation into E. coli. The presence of the Tn1331-encoded aac(6′)-Ib gene conferring amikacin resistance only in type 2 transconjugants may explain the 16-fold increase in the MIC of amikacin observed for type 2 as compared with those for type 1 ( Table 2 ). The aph(3′)-VIa gene, which also confers amikacin resistance, was not detected by PCR in the K. pneumoniae parental isolates.
Conclusions
Generally, in Vibrio cholerae 16 and Enterobacteriaceae 4, 33, 34 from Argentina, ESBLs and TEM-1-like enzymes are encoded on the at Pennsylvania State University on March 1, 2013 http://jac.oxfordjournals.org/ Downloaded from same megaplasmid, which, additionally, harbours genetic determinants conferring resistance to other kinds of antibiotics, such as aminoglycosides, trimethoprim-sulfamethoxazole, chloramphenicol and tetracycline. Therefore, the use of any of these drugs in nosocomial acquired infections may lead to cross-selection of extended-spectrum cephalosporin resistance.
Worldwide, few descriptions of strains with two or more ESBLs have been reported, and all of those that have been reported involve TEM-or SHV-derived enzymes. We identified here two ESBLs, CTX-M-2 and PER-2, in a single multiresistant isolate, the first report of this ESBL combination in the same strain. The fact that bla CTX-M-2 and bla PER-2 were harboured in two different megaplasmids suggests a differential spread of these genes, which correlates well with their different prevalences (60% versus 10%, respectively 4, 33, 34 ) observed in the Argentinean isolates. After successive antibiotic treatments, the last of them with ciprofloxacin, K. pneumoniae M1826 could be selected. The selection of these multiresistant bacteria in the hospital environment could be due, amongst other factors, to excessive and/or inappropriate antibiotic use, particularly of empirically prescribed broad-spectrum agents.
